MCID: OPT003
MIFTS: 49

Opiate Dependence

Categories: Mental diseases

Aliases & Classifications for Opiate Dependence

MalaCards integrated aliases for Opiate Dependence:

Name: Opiate Dependence 12 15
Opioid Dependence 73 54 17
Opioid-Related Disorders 70
Opioid Type Dependence 12
Opiate Addiction 70

Classifications:



External Ids:

Disease Ontology 12 DOID:2559
ICD9CM 34 304.00
MeSH 44 D009293
SNOMED-CT 67 75544000
ICD10 32 F11.2
UMLS 70 C0027412 C0524662

Summaries for Opiate Dependence

Disease Ontology : 12 A drug dependence that involves the continued use of opiate drugs despite despite problems related to use of the substance.

MalaCards based summary : Opiate Dependence, also known as opioid dependence, is related to opioid dependence 1 and opioid addiction. An important gene associated with Opiate Dependence is ODS1 (Opioid Dependence, Susceptibility To, 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Guaifenesin and Phenylpropanolamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, brain and amygdala, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 73 Opioid use disorder (OUD) is a substance use disorder relating to the use of an opioid. Any such... more...

Related Diseases for Opiate Dependence

Diseases related to Opiate Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 199)
# Related Disease Score Top Affiliating Genes
1 opioid dependence 1 32.9 OPRM1 ODS1
2 opioid addiction 32.1 OPRM1 OPRK1 OPRD1 DRD2
3 morphine dependence 31.2 PENK PDYN OPRM1 OPRK1 OPRD1 FOS
4 heroin dependence 31.2 SLC6A4 SLC6A3 PDYN OPRM1 OPRD1 DRD2
5 sexual disorder 30.8 SLC6A4 POMC IGF1
6 dysthymic disorder 30.3 SLC6A4 SLC6A3 POMC
7 obsessive-compulsive personality disorder 30.2 SLC6A4 DRD3
8 neonatal abstinence syndrome 30.2 PDYN OPRM1 OPRK1 OPRD1
9 schizoaffective disorder 30.2 SLC6A4 DRD3 DRD2
10 post-traumatic stress disorder 30.2 SLC6A4 POMC DRD2
11 somatoform disorder 30.1 TPH1 SLC6A4 OPRM1 NGF
12 cocaine abuse 30.0 SLC6A4 SLC6A3 OPRK1 NGF DRD2
13 constipation 30.0 TH SLC6A4 PDYN OPRM1 OPRK1
14 phobic disorder 29.9 SLC6A4 SLC6A3 POMC DRD2
15 mental depression 29.8 TPH1 SLC6A4 SLC6A3 POMC DRD2 CREB1
16 borderline personality disorder 29.8 TPH1 SLC6A4 SLC6A3 DRD2
17 antisocial personality disorder 29.8 SLC6A4 SLC6A3 DRD2 ANKK1
18 panic disorder 29.8 TPH1 SLC6A4 SLC6A3 POMC DRD3 DRD2
19 conduct disorder 29.7 TPH1 SLC6A4 SLC6A3 POMC DRD2
20 alcohol use disorder 29.7 SLC6A4 SLC6A3 OPRM1 DRD3 DRD2 CREB1
21 personality disorder 29.7 TPH1 TH SLC6A4 SLC6A3 DRD3 DRD2
22 substance abuse 29.6 SLC6A4 SLC6A3 POMC PDYN OPRM1 DRD3
23 restless legs syndrome 29.6 TH SLC6A4 SLC6A3 POMC DRD3 DRD2
24 opioid abuse 29.5 SLC6A3 POMC PENK PDYN OPRM1 OPRK1
25 withdrawal disorder 29.5 SLC6A3 POMC PENK PDYN OPRM1 OPRK1
26 major depressive disorder 29.4 TPH1 SLC6A4 SLC6A3 POMC OPRM1 NGF
27 anxiety 29.4 TPH1 TH SLC6A4 SLC6A3 POMC PDYN
28 mood disorder 29.3 TPH1 TH SLC6A4 SLC6A3 POMC DRD3
29 tobacco addiction 29.3 TPH1 SLC6A4 SLC6A3 PDYN OPRM1 DRD3
30 sleep disorder 29.3 TH SLC6A4 SLC6A3 POMC PDYN IGF1
31 drug dependence 29.2 SLC6A4 SLC6A3 POMC PENK PDYN OPRM1
32 pain agnosia 29.0 POMC PENK PDYN OPRM1 OPRK1 OPRD1
33 cocaine dependence 29.0 SLC6A4 SLC6A3 POMC PDYN OPRM1 OPRK1
34 bipolar disorder 28.9 TPH1 TH SLC6A4 SLC6A3 PDYN NGF
35 substance dependence 28.9 TPH1 SLC6A4 SLC6A3 POMC PDYN OPRM1
36 alcohol dependence 28.8 TPH1 TH SLC6A4 SLC6A3 POMC PDYN
37 attention deficit-hyperactivity disorder 28.7 TPH1 TH SLC6A4 SLC6A3 OPRM1 NGF
38 schizophrenia 28.4 TPH1 TH SLC6A4 SLC6A3 POMC PDYN
39 wissler-fanconi syndrome 10.4 TPH1 POMC
40 functionless pituitary adenoma 10.4 POMC IGF1
41 acidophil adenoma 10.4 POMC IGF1
42 myofascial pain syndrome 10.4 POMC NGF
43 barbiturate abuse 10.4 POMC OPRM1
44 somatization disorder 10.4 SLC6A4 POMC
45 pituitary infarct 10.3 POMC IGF1
46 adjustment disorder 10.3 TH SLC6A4 POMC
47 prolactin producing pituitary tumor 10.3 POMC DRD2
48 neurotic disorder 10.3 SLC6A4 POMC NGF
49 polysubstance abuse 10.3 DRD3 DRD2
50 alcohol-induced mental disorder 10.3 SLC6A4 DRD2

Graphical network of the top 20 diseases related to Opiate Dependence:



Diseases related to Opiate Dependence

Symptoms & Phenotypes for Opiate Dependence

MGI Mouse Phenotypes related to Opiate Dependence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 CREB1 DRD2 DRD3 FOS NGF NPFF
2 homeostasis/metabolism MP:0005376 10.25 CREB1 DRD2 DRD3 FOS IGF1 NGF
3 endocrine/exocrine gland MP:0005379 10.18 CREB1 DRD2 FOS IGF1 OPRK1 OPRM1
4 growth/size/body region MP:0005378 10.18 CREB1 DRD2 DRD3 FOS IGF1 NGF
5 adipose tissue MP:0005375 10.11 DRD2 DRD3 FOS IGF1 OPRM1 PDYN
6 integument MP:0010771 10.1 DRD2 FOS IGF1 NGF OPRD1 OPRK1
7 nervous system MP:0003631 10 CREB1 DRD2 DRD3 FOS IGF1 NGF
8 no phenotypic analysis MP:0003012 9.56 DRD2 NGF OPRD1 OPRM1 PDYN PENK
9 normal MP:0002873 9.36 CREB1 DRD2 FOS IGF1 KPNA3 NGF

Drugs & Therapeutics for Opiate Dependence

Drugs for Opiate Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 290)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
2
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
3
Lofexidine Approved, Investigational Phase 4 31036-80-3 30668
4
Clonidine Approved Phase 4 4205-90-7 2803
5
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
6
Ribavirin Approved Phase 4 36791-04-5 37542
7
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
8
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
9
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
10
Norepinephrine Approved Phase 4 51-41-2 439260
11
Remifentanil Approved Phase 4 132875-61-7 60815
12
Ondansetron Approved Phase 4 99614-02-5 4595
13
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
14
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
15
Nevirapine Approved Phase 4 129618-40-2 4463
16
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
17
Acetaminophen Approved Phase 4 103-90-2 1983
18
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
19
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
20
Ibuprofen Approved Phase 4 15687-27-1 3672
21
Cobicistat Approved Phase 4 1004316-88-4
22
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
23
Menthol Approved Phase 4 2216-51-5 16666
24
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
25
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
26
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
27
Nicotine Approved Phase 4 54-11-5 942 89594
28
Methadone Approved Phase 4 76-99-3 4095
29
Morphine Approved, Investigational Phase 4 57-27-2 5288826
30
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
31
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
32
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604
33
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
34
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
35
Trichostatin A Experimental Phase 4 58880-19-6
36 Respiratory System Agents Phase 4
37 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
38 Antitussive Agents Phase 4
39 Adrenergic alpha-Agonists Phase 4
40 Adrenergic Agents Phase 4
41 Adrenergic Agonists Phase 4
42 Antihypertensive Agents Phase 4
43 Neurotransmitter Agents Phase 4
44 Gastrointestinal Agents Phase 4
45 Detox adjuvant Phase 4
46 Excitatory Amino Acid Antagonists Phase 4
47 Analgesics, Non-Narcotic Phase 4
48 Anesthetics, General Phase 4
49 Anesthetics, Intravenous Phase 4
50 Sympatholytics Phase 4

Interventional clinical trials:

(show top 50) (show all 665)
# Name Status NCT ID Phase Drugs
1 SPNS Buprenorphine and Integrated HIV Care Evaluation and Support Center: Integration of Buprenorphine and HIV Treatment Using the OASIS Model Unknown status NCT00241930 Phase 4
2 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
3 Integrating Buprenorphine Into the SFGH AIDS Program (Patient Evaluation Study) Completed NCT00263458 Phase 4
4 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Completed NCT00007527 Phase 4 naloxone;buprenorphine
5 Feasibility, Mechanism of Action and Potential Side Effects of Extended Release Depot Naltrexone in Opioid Dependent Patients Completed NCT01471145 Phase 4 Naltrexone
6 A Phase 4, Pilot, Open-label Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration Completed NCT01453374 Phase 4 VIVITROL 380mg
7 A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population Completed NCT02038790 Phase 4 Suboxone Sublingual Film;Zubsolv sublingual tablets
8 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Treatment in Opioid Dependent Chronic Back Pain Patients Completed NCT01559454 Phase 4 Methadone;Buprenorphine/naloxone
9 Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth Completed NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
10 A Randomized Controlled Trial Comparing Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
11 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence Completed NCT00555425 Phase 4
12 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
13 A Feasibility Study for Testing the Effects of Extended-release Naltrexone (Vivitrol) on Recidivism and Other Participant Outcomes in Drug Court Settings Completed NCT02978417 Phase 4 Naltrexone for extended-release injectable suspension;Oral naltrexone
14 Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy Completed NCT01045278 Phase 4 Pegylated interferon-alfa-2b and ribavirin
15 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
16 An Open Multi-center Trial of Suboxone® (Buprenorphine/Naloxone) Treatment Among Opiate-Dependent Subjects Completed NCT00901875 Phase 4 Buprenorphine + naloxone (Suboxone);Buprenorphine + naloxone (Suboxone)
17 Counseling for Primary Care Office-based Buprenorphine Completed NCT00595764 Phase 4
18 Effects of Ketamine On Precipitated Opioid Withdrawal Under General Anaesthesia Completed NCT00300794 Phase 4 Ketamine
19 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
20 Buprenorphine Extended-release in Jail and at Re-entry: Open-label Randomized Controlled Trial vs. Daily Sublingual Buprenorphine-naloxone Completed NCT03604159 Phase 4 Buprenorphine Extended Release;Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets)
21 Relapse Prevention to Reduce HIV Among Women Prisoners Completed NCT00763958 Phase 4 Placebo;Buprenorphine
22 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
23 A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219 Completed NCT01903005 Phase 4 Higher bioavailability BNX sublingual tablets
24 Evaluation of Preference for a Buprenorphine-based Maintenance Therapy, After a Switch From Buprenorphine Alone (Subutex®) to the Buprenorphine/Naloxone Combination (Suboxone®), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy Completed NCT00684073 Phase 4 buprenorphine;buprenorphine/naloxone
25 An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression Completed NCT02200406 Phase 4 Desvenlafaxine
26 Neurocognitive Effects of Opiate Agonist Treatment Completed NCT01733693 Phase 4 Buprenorphine;Methadone
27 Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection Completed NCT02616523 Phase 4 Dexmedetomidine;Lidocaine;Fentanyl
28 Feasibility Study of Take-Home LAAM Medication Completed NCT00000300 Phase 4 LAAM
29 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
30 A Comparison of PR Oxycodone/Naloxone and PR Oxycodone After Cardiac Surgery Completed NCT01374763 Phase 4 Oxycodone;Prolonged-release oxycodone/naloxone
31 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
32 Gabapentin Regimens and Their Effects on Opioid Consumption Completed NCT03334903 Phase 4 Gabapentin
33 Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia: Randomize Double Blind Clinical Trial Completed NCT02992938 Phase 4 Acetazolamide;Placebo Oral Tablet
34 Naltrexone: Consummatory Behaviors in Alcoholic Women Completed NCT00000448 Phase 4 naltrexone;Placebo
35 A Double-blind Randomised Controlled Clinical Trial of Lofexidine Versus Diazepam in the Management of the Opioid Withdrawal Syndrome During Inpatient Detoxification in Singapore Completed NCT01675648 Phase 4 Lofexidine;Diazepam;Placebo for Lofexidine;Placebo for Diazepam
36 A Multicentre, Randomised, Open-label, Active-controlled Trial of the Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France Completed NCT00955162 Phase 4 Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)
37 VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison Completed NCT01563718 Phase 4 naltrexone for extended release injectable suspension
38 Hydromorphone PCA or Hydromorphone PCA With Ketamine for Acute Postoperative Pain Relief in Opioid-Dependent Chronic Pain Patients Completed NCT01591382 Phase 4 Ketamine;Placebo;Hydromorphone PCA
39 A Pharmacokinetic Study to Evaluate the Interaction Between Nevirapine (Viramune®) and Methadone in HIV-1 Infected, Opioid-dependent Adults on Stable Methadone Maintenance Therapy Completed NCT00273988 Phase 4 nevirapine
40 The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients Completed NCT02085577 Phase 4 (S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml;Isotonic sodium chloride 0.9 percent;Paracetamol 1 g;Morphine Sulphate 1 mg/ml;Morphine Sulphate 1 mg/ml;Ondansetron 2 mg/ml;Usual daily opioids;Morphine Sulphate 1 mg/ml;Sufentanil 5 microgram/ml
41 Houston Emergency Opioid Engagement System (HEROES) Recruiting NCT03396276 Phase 4 Suboxone
42 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings Recruiting NCT03089983 Phase 4 Buprenorphine Naloxone;Methadone;Isoniazid;Rifapentine
43 Long Acting Naltrexone for Opioid Addiction: the Importance of Mental, Physical and Societal Factors for Sustained Abstinence and Recovery Recruiting NCT03647774 Phase 4 Extended release naltrexone
44 Houston Emergency Engagement System for Youths and Adolescents Recruiting NCT04811014 Phase 4 Buprenorphine, Naloxone Drug Combination
45 Efficacy of Non-Opioid Analgesics in the Management of Pain Following Endoscopic Sinus Surgery: A Multi-Institutional Randomized Controlled Trial Recruiting NCT03783702 Phase 4 OxyCODONE 5 Mg Oral Tablet;Ibuprofen 600 Mg Oral Tablet;Acetaminophen 650 MG Oral Tablet
46 Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Switch Followed by Sofosbuvir/Velpatasvir (SOF/VEL) Antiviral HCV Therapy Followed by Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Simplification in HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy - A Pilot Feasibility Study Recruiting NCT03549312 Phase 4 Genvoya;Epclusa;Biktarvy
47 The Analgesic Efficacy of Continuous Sub-fascial Bupivacaine Infusion and Lidocaine Patches in Post-cesarean Patients With Opiate Use Disorder: A Comparative Efficacy Analysis Recruiting NCT04033562 Phase 4 Lidocaine patch
48 Increasing Access to Hepatitis C Treatment in Opioid Endemic Rural Areas: The Kentucky Viral Hepatitis Treatment (KeY Treat) Study Recruiting NCT03949764 Phase 4 Sofosbuvir/velpatasvir (Epclusa®)
49 Neurocomputational Mechanisms of Mood Improvement Recruiting NCT04276259 Phase 4 Buprenorphine;Naltrexone;Oral Placebo;IM Placebo
50 Bridging Care to HCV Treatment Among Opiate Dependent Patients on Buprenorphine/Naloxone Maintenance Therapy: A Pilot Study of Treating HCV With Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic Active, not recruiting NCT03235154 Phase 4 sofosbuvir/velpatasvir

Search NIH Clinical Center for Opiate Dependence

Inferred drug relations via UMLS 70 / NDF-RT 51 :


CLONIDINE HCL PWDR
Clonidine Hydrochloride
Levomethadyl
Levomethadyl Acetate Hydrochloride
Methadone
Methadone Hydrochloride
nalmefene
Nalmefene hydrochloride
Naloxone Hydrochloride
Naltrexone
Naltrexone hydrochloride

Genetic Tests for Opiate Dependence

Anatomical Context for Opiate Dependence

MalaCards organs/tissues related to Opiate Dependence:

40
Pituitary, Brain, Amygdala, Cortex, Liver, Spinal Cord, Bone

Publications for Opiate Dependence

Articles related to Opiate Dependence:

(show top 50) (show all 3578)
# Title Authors PMID Year
1
Functional impact of a single-nucleotide polymorphism in the OPRD1 promoter region. 61 54
20300121 2010
2
Shared mechanisms for opioid tolerance and a transition to chronic pain. 54 61
20357116 2010
3
Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. 61 54
19403243 2009
4
ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. 54 61
18424454 2008
5
Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? 61 54
18193922 2008
6
Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. 61 54
17416470 2007
7
The opioid system in alcohol and drug dependence: family-based association study. 54 61
17503481 2007
8
Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. 54 61
16583408 2006
9
In-vitro and in-vivo characterization of a buprenorphine delivery system. 61 54
16536895 2006
10
A functional prodynorphin promoter polymorphism and opioid dependence. 61 54
16314761 2005
11
Novel exonic mu-opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence. 54 61
15558714 2005
12
A genetic association study of the mu opioid receptor and severe opioid dependence. 61 54
12960749 2003
13
Introducing a new recruitment approach to sample collection for genetic association studies in opioid dependence. 54 61
12648891 2003
14
D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. 54 61
12497624 2003
15
The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. 54 61
11054765 2000
16
The DRD2 gene in psychiatric and neurological disorders and its phenotypes. 61 54
11256581 2000
17
Addiction and its reward process through polymorphisms of the D2 dopamine receptor gene: a review. 54 61
10881203 2000
18
Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1). 61 54
9756053 1998
19
Dopamine D3 receptor gene variants and substance abuse in schizophrenia. 54 61
9702743 1998
20
The role of glutamate in physical dependence on opioids. 54 61
9517399 1998
21
Glutamate in opioid dependence. 54 61
9365966 1997
22
Human pharmacology of the opioid neuropeptide dynorphin A(1-13). 54 61
9190848 1997
23
Tobacco use severity in relation to opioid misuse and dependence among adult tobacco users with chronic pain: The moderating role of pain-related anxiety. 61
33545622 2021
24
CBT and CFT for Chronic Pain. 61
33791876 2021
25
A review of the existing literature on buprenorphine pharmacogenomics. 61
33154520 2021
26
Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. 61
33640039 2021
27
The Impact of Mental Health and Substance Use on Opioid Demand After Hip Fracture Surgery. 61
33201045 2021
28
The Psychological Effects of Musculoskeletal Trauma. 61
33475305 2021
29
Early life maternal deprivation attenuates morphine induced inhibition in lateral paragigantocellularis neurons in adult rats. 61
33482287 2021
30
Sexually dimorphic neuroimmune response to chronic opioid treatment and withdrawal. 61
33485944 2021
31
Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study). 61
33665469 2021
32
Quality of Life in Opioid Replacement Therapy: A Naturalistic Cross-Sectional Comparison of Methadone/Levomethadone, Buprenorphine, and Diamorphine Patients. 61
33784698 2021
33
Sex-dependent effects of an Hnrnph1 mutation on fentanyl addiction-relevant behaviors but not antinociception in mice. 61
33145940 2021
34
Opioid Use Following Inpatient Versus Outpatient Total Joint Arthroplasty. 61
33439611 2021
35
Association of diabetes mellitus with postoperative opioid consumption in patients undergoing primary unilateral hip arthroplasty. 61
32096444 2021
36
Inequalities in general practice remote consultations: A systematic review. 61
33712502 2021
37
[Opioid Substitution Treatment in Germany: Physicians' View on the Effects of the 3rd Revision of the Narcotic Drugs Prescription Ordinance]. 61
33647992 2021
38
Opioid Dependence After Lung Cancer Resection: Institutional Analysis of State Prescription Drug Database. 61
33221948 2021
39
Early Opioid Consumption Patterns After Anterior Cervical Spine Surgery. 61
33783369 2021
40
Continuous local bupivacaine wound infusion reduces oral opioid use for acute postoperative pain control following myelomeningocele repair. 61
33485023 2021
41
Evaluation of the German biographic screening interview for fetal alcohol spectrum disorder (BSI-FASD). 61
33664281 2021
42
High Genetic Addiction Risk Score (GARS) in Chronically Prescribed Severe Chronic Opioid Probands Attending Multi-pain Clinics: an Open Clinical Pilot Trial. 61
33683627 2021
43
Automated quantification of opioid withdrawal in neonatal rat pups using Ethovision® XT software. 61
33529734 2021
44
Preclinical pharmacokinetic study of speciociliatine, a kratom alkaloid, in rats using an UPLC-MS/MS method. 61
33277117 2021
45
Opioid painkiller dependence in a sample of elderly medical inpatients. 61
33594719 2021
46
Retention in the Austrian opioid agonist treatment system: a national prospective cohort study. 61
33627159 2021
47
A national database propensity score-matched comparison of minimally invasive and open colectomy for long-term opioid use. 61
33569727 2021
48
Naltrexone treatment for prolonged grief disorder: study protocol for a randomized, triple-blinded, placebo-controlled trial. 61
33522931 2021
49
The Oxford Catalogue of Opioids: A systematic synthesis of opioid drug names and their pharmacology. 61
33608948 2021
50
A Retrospective Cross-Sectional Study of the Effect of Liposomal Bupivacaine on Postoperative Opioid Prescribing After Third Molar Extraction. 61
33744242 2021

Variations for Opiate Dependence

Expression for Opiate Dependence

Search GEO for disease gene expression data for Opiate Dependence.

Pathways for Opiate Dependence

Pathways related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 POMC PENK PDYN OPRM1 OPRK1 OPRD1
2
Show member pathways
13.41 POMC PENK PDYN OPRM1 OPRK1 OPRD1
3
Show member pathways
12.81 TH SLC6A3 IGF1 FOS DRD3 DRD2
4 12.38 TPH1 TH POMC OPRM1 NGF CREB1
5 12.16 POMC FOS DRD2 CREB1
7 11.93 TPH1 TH SLC6A4 NGF CREB1
8 11.9 POMC OPRM1 FOS CREB1
9 11.79 POMC OPRM1 OPRD1 FOS
10
Show member pathways
11.76 TH DRD3 DRD2
11 11.7 POMC FOS CREB1
12 11.64 POMC FOS CREB1
13 11.61 TH NGF IGF1
14
Show member pathways
11.5 TH SLC6A3 PDYN FOS DRD2 CREB1
15 11.43 TH FOS CREB1
16
Show member pathways
11.3 TH SLC6A4 SLC6A3
17 10.76 TH POMC DRD2 ANKK1
18
Show member pathways
10.38 TH SLC6A4 SLC6A3 DRD3 DRD2

GO Terms for Opiate Dependence

Cellular components related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 10.05 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 DRD3
2 axon GO:0030424 9.95 TH SLC6A3 PENK OPRM1 NGF DRD2
3 dendrite GO:0030425 9.92 TH PENK PDYN OPRM1 OPRK1 NPFF
4 neuron projection GO:0043005 9.86 TPH1 TH SLC6A4 SLC6A3 OPRM1 OPRK1
5 neuronal cell body GO:0043025 9.85 TH SLC6A3 PENK PDYN OPRK1
6 perikaryon GO:0043204 9.85 TH PENK OPRM1 OPRK1 NPFF DRD2
7 membrane raft GO:0045121 9.8 SLC6A4 SLC6A3 OPRM1 OPRD1
8 integral component of postsynaptic membrane GO:0099055 9.55 SLC6A4 SLC6A3 OPRM1 OPRK1 DRD2
9 dopaminergic synapse GO:0098691 9.48 SLC6A3 DRD2
10 spine apparatus GO:0097444 9.43 OPRM1 OPRD1
11 axon terminus GO:0043679 9.43 PENK PDYN OPRK1 OPRD1 NPFF DRD2
12 integral component of presynaptic membrane GO:0099056 9.1 SLC6A4 SLC6A3 OPRM1 OPRK1 OPRD1 DRD2

Biological processes related to Opiate Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.32 POMC PENK OPRM1 OPRK1 OPRD1 IGF1
2 G protein-coupled receptor signaling pathway GO:0007186 10.18 POMC PENK PDYN OPRM1 OPRK1 OPRD1
3 cytokine-mediated signaling pathway GO:0019221 10.02 POMC OPRM1 OPRD1 FOS
4 chemical synaptic transmission GO:0007268 10.01 PENK PDYN OPRK1 NPFF
5 aging GO:0007568 9.98 SLC6A3 PENK FOS CREB1
6 response to hypoxia GO:0001666 9.98 TH SLC6A4 PENK DRD2 CREB1
7 response to lipopolysaccharide GO:0032496 9.96 TH PENK OPRM1 FOS
8 response to toxic substance GO:0009636 9.9 SLC6A4 PENK FOS DRD2
9 circadian rhythm GO:0007623 9.89 TPH1 SLC6A4 CREB1
10 memory GO:0007613 9.89 TH SLC6A4 NGF CREB1
11 cellular response to growth factor stimulus GO:0071363 9.87 TH OPRD1 CREB1
12 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.86 OPRM1 OPRK1 OPRD1
13 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.86 OPRM1 OPRK1 OPRD1
14 excitatory postsynaptic potential GO:0060079 9.86 OPRM1 NPFF DRD2
15 response to drug GO:0042493 9.86 TH SLC6A4 SLC6A3 NPFF FOS DRD3
16 sensory perception of pain GO:0019233 9.85 PENK OPRM1 OPRK1
17 social behavior GO:0035176 9.83 TH SLC6A4 DRD3
18 visual learning GO:0008542 9.82 DRD3 DRD2 CREB1
19 response to radiation GO:0009314 9.8 PENK OPRM1 OPRK1
20 positive regulation of multicellular organism growth GO:0040018 9.8 SLC6A3 DRD2 CREB1
21 response to cocaine GO:0042220 9.8 SLC6A3 OPRM1 OPRK1 DRD3 DRD2
22 locomotory behavior GO:0007626 9.8 TH SLC6A3 PENK OPRK1 DRD3 DRD2
23 response to light stimulus GO:0009416 9.79 TH FOS DRD2
24 response to immobilization stress GO:0035902 9.78 TPH1 TH FOS
25 regulation of sensory perception of pain GO:0051930 9.78 OPRM1 OPRK1 OPRD1 NPFF
26 response to nicotine GO:0035094 9.77 TH SLC6A3 PENK DRD2 CREB1
27 eating behavior GO:0042755 9.76 TH OPRM1 OPRK1 OPRD1
28 negative regulation of cytosolic calcium ion concentration GO:0051481 9.75 OPRM1 DRD3 DRD2
29 behavioral response to cocaine GO:0048148 9.74 OPRK1 DRD3 DRD2
30 neurotransmitter biosynthetic process GO:0042136 9.73 TH SLC6A4 SLC6A3
31 sensory perception GO:0007600 9.73 PENK PDYN OPRM1 OPRK1
32 positive regulation of renal sodium excretion GO:0035815 9.72 DRD3 DRD2
33 G protein-coupled receptor internalization GO:0002031 9.72 DRD3 DRD2
34 startle response GO:0001964 9.72 PENK DRD2
35 prepulse inhibition GO:0060134 9.72 SLC6A3 DRD3 DRD2
36 negative regulation of voltage-gated calcium channel activity GO:1901386 9.71 DRD3 DRD2
37 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.71 DRD3 DRD2
38 dopamine biosynthetic process GO:0042416 9.71 TH SLC6A3
39 synaptic transmission, dopaminergic GO:0001963 9.71 TH DRD3 DRD2
40 monoamine transport GO:0015844 9.7 SLC6A4 SLC6A3
41 aromatic amino acid family metabolic process GO:0009072 9.7 TPH1 TH
42 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.7 DRD3 DRD2
43 response to ethanol GO:0045471 9.7 TH SLC6A3 PENK OPRM1 OPRK1 DRD3
44 behavioral response to ethanol GO:0048149 9.69 OPRM1 DRD2
45 adenohypophysis development GO:0021984 9.69 SLC6A3 DRD2
46 opioid receptor signaling pathway GO:0038003 9.69 OPRM1 OPRK1 OPRD1
47 acute inflammatory response to antigenic stimulus GO:0002438 9.68 OPRM1 NPFF
48 regulation of potassium ion transport GO:0043266 9.67 DRD3 DRD2
49 hyaloid vascular plexus regression GO:1990384 9.67 TH SLC6A3 DRD2
50 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.65 DRD3 DRD2

Molecular functions related to Opiate Dependence according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.88 SLC6A3 POMC NPFF NGF DRD2
2 peptide binding GO:0042277 9.67 OPRM1 OPRK1 OPRD1
3 monoamine transmembrane transporter activity GO:0008504 9.51 SLC6A4 SLC6A3
4 receptor serine/threonine kinase binding GO:0033612 9.46 OPRK1 OPRD1
5 dopamine neurotransmitter receptor activity GO:0004952 9.43 DRD3 DRD2
6 opioid receptor binding GO:0031628 9.4 PENK PDYN
7 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.37 TPH1 TH
8 neuropeptide binding GO:0042923 9.33 OPRM1 OPRK1 OPRD1
9 opioid peptide activity GO:0001515 9.32 PENK PDYN
10 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.26 DRD3 DRD2
11 opioid receptor activity GO:0004985 9.13 OPRM1 OPRK1 OPRD1
12 dopamine binding GO:0035240 8.8 TH SLC6A3 DRD2

Sources for Opiate Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....